EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The characterization of serum proteomics and metabolomics across the cancer trajectory in chronic hepatitis B‐related liver diseases

Jin Xiao, Hang Liu, Jun Yao, Shuang Yang, Fenglin Shen, KunPeng Bu, Zhenxin Wang, Fan Liu, Ningshao Xia, Quan Yuan, Hong Shu, Yueting Xiong und 1 weitere

VIEW · 2024

DOI: 10.1002/viw.20240031 ↗

Kurz gefasst

Fachartikel in der Zeitschrift VIEW, 2024. Verfasst von Jin Xiao und 12 weiteren Autor:innen. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, National Key Research and Development Program of China.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hepatocellular carcinoma (HCC) is a deadly cancer that emerges from a continuous progression of liver cells from normal to abnormal, often following infections by hepatitis B/C viruses (HBV/HCV), liver fibrosis, and liver cirrhosis (LC), ultimately culminating in cancer. However, there is currently limited systematic molecular analysis of biomarkers at different stages of HCC progression using multi‐omics approaches. We carried out an innovative pipeline by utilizing targeted proteomics and metabolomics to identify potential biomarkers for early detection of HCC in 316 participants, including healthy adults and patients diagnosed with HBV, HCV, LC, and HCC from three independent cohorts. We first established a detailed database of candidate biomarkers for HCC containing 3059 proteins and 103 metabolites, and identified pivotal candidates implicated in the progressive trajectory of liver cancers. Through our developed DeepPRM, scheduled multiple reaction monitoring (MRM)‐targeted approach, and machine learning‐based computational pipeline, we identified an eight‐biomolecular‐based combination with an accuracy rate of 91.43% for early diagnosis of HCC, and a 12‐biomolecular‐based combination with an accuracy rate of 80.00% for detecting changes in HBV–LC progression. These two biomarker combinations significantly improved accuracy compared to traditional tumor biomarkers. Our extensive analysis provides valuable proteomic and metabolomic data resources that will contribute to a deeper understanding of liver disease progression and enhance the identification of potential therapeutic targets.

Förderung

  • National Natural Science Foundation of China
  • National Key Research and Development Program of China

Zitieren

APA

Xiao, J., Liu, H., Yao, J., Yang, S., Shen, F., Bu, K., Wang, Z., Liu, F., Xia, N., Yuan, Q., Shu, H., Xiong, Y., & Liu, X. (2024). The characterization of serum proteomics and metabolomics across the cancer trajectory in chronic hepatitis B‐related liver diseases. VIEW. https://doi.org/10.1002/viw.20240031

Vancouver

Xiao J, Liu H, Yao J, Yang S, Shen F, Bu K, et al. The characterization of serum proteomics and metabolomics across the cancer trajectory in chronic hepatitis B‐related liver diseases. VIEW. 2024. doi:10.1002/viw.20240031

BibTeX
@article{Xiao2024,
  author = {Xiao, Jin and Liu, Hang and Yao, Jun and Yang, Shuang and Shen, Fenglin and Bu, KunPeng and Wang, Zhenxin and Liu, Fan and Xia, Ningshao and Yuan, Quan and Shu, Hong and Xiong, Yueting and Liu, Xiaohui},
  title = {The characterization of serum proteomics and metabolomics across the cancer trajectory in chronic hepatitis B‐related liver diseases},
  journal = {VIEW},
  year = {2024},
  doi = {10.1002/viw.20240031}
}
Kostenlos starten →